H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $10.
According to TipRanks data, the analyst has a success rate of 35.4% and a total average return of 16.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following Sangamo's latest quarterly report, there's an anticipation of a significant development pathway for the Fabry program aligned with the FDA. The subsequent discussions centered on the program's future, with partnership negotiations reportedly in the advanced phase. The expectation is set for potentially favorable data outcomes by the third quarter of 2025, followed by anticipated regulatory approval in 2026, and a partnership deal announcement is expected imminently.
The firm anticipates that the formation of partnerships concerning the Fabry program and the comprehensive data from the pivotal study will act as primary catalysts. It is believed that the potential rise in the stock's value will be propelled by the proof of concept for the company's proprietary ZFP transcription factor neurology programs.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
H.C. Wainwright分析师Patrick Trucchio维持$Sangamo Therapeutics (SGMO.US)$买入评级，维持目标价10美元。
根据TipRanks数据显示，该分析师近一年总胜率为35.4%，总平均回报率为16.7%。
此外，综合报道，$Sangamo Therapeutics (SGMO.US)$近期主要分析师观点如下：
在Sangamo最新的季度报告后，外界对与FDA相关的Fabry项目的发展路径充满期待。后续讨论集中在该项目的未来，据报道合作谈判已进入爱文思控股阶段。预计到2025年第三季度可能会有有利的数据结果，接下来预计将在2026年获得监管批准，并有望很快宣布合作协议。
该公司预计，围绕Fabry项目的合作关系形成和关键研究的完整数据将成为主要催化剂。人们相信，公司的专有ZFP转录因子神经学项目的概念证明将推动股票价值的潜在上涨。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
